Search results
Results from the WOW.Com Content Network
By using CRISPR technology, they aimed to "knock out" this gene in the muscle cells of their forearm. The intent was to disrupt the gene's function, potentially allowing for localized muscle growth. [14] [15] [16] Zayner's CRISPR kit was displayed at the Cooper Hewitt's 2019 Nature Design Triennial. [17]
Ishino was born in Kyoto Prefecture, Japan.He received his BS, MS and PhD in 1981, 1983 and 1986, respectively, from Osaka University. [1] From 1987 to 1989, he served as a post-doctoral fellow in Dieter Söll's laboratory at Yale University.
Francisco Juan Martínez Mojica [a] (born 5 October 1963) is a Spanish molecular biologist and microbiologist at the University of Alicante in Spain.He is known for his discovery of repetitive, functional DNA sequences in bacteria which he named CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats).
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
He co-developed Multiplex Automated Genome Engineering (MAGE) and optimized CRISPR/Cas9, discovered by Jennifer Doudna and Emmanuelle Charpentier for engineering a variety of genomes ranging from yeast to human. [62] His laboratory's use of CRISPR in human induced pluripotent stem cells (hiPS) is the latest contender for precise gene therapy. [64]
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. [3] NTLA-2002 is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 1 / 2 studies. [4]
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and open up specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within living organisms.
Doudna was introduced to CRISPR by Jillian Banfield in 2006 who had found Doudna by way of a Google search, having typed "RNAi and UC Berkeley" into her browser, and Doudna's name came up at the top of the list. [37] [38] In 2012, Doudna and her colleagues made a new discovery that reduces the time and work needed to edit genomic DNA.